<DOC>
	<DOC>NCT02281448</DOC>
	<brief_summary>Single centre, two-way crossover, randomised, open-label study in 20 healthy female volunteers.The volunteers received an oral single-dose of a combined contraceptive containing with an oral once daily dose of 1200 mg of BIA 2-093</brief_summary>
	<brief_title>Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.</brief_title>
	<detailed_description>Single centre, two-way crossover, randomised, open-label study in 20 healthy female volunteers.The volunteers received an oral single-dose of a combined contraceptive containing 30 μg ethinyloestradiol and 150 μg levonorgestrel on two occasions ─ once as such and once after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 for 15 days separated by a washout period of at least 3 weeks.</detailed_description>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Premenopausal female; Able and willing to give written informed consent; Aged 18 to 40 years, inclusive; Not pregnant or breastfeeding; Body mass index (BMI) between 19 and 30 kg/m2, inclusive; Healthy as determined by medical history, physical examination, complete neurological examination, vital signs, and 12lead ECG; Clinical laboratory tests with clinically acceptable results at screening and admission to the first period; Negative tests for HBsAg, antiHCV Ab and HIV1 and HIV2 Ab at screening; Negative test for drugs of abuse at screening; Nonsmoker or smokes less than 10 cigarettes or equivalent per day; Agreed to either practice abstinence or use a doublebarrier or intrauterine device from screening until the followup visit; Negative pregnancy test at screening and admission to the first period. Had any contraindication to the use of oral contraceptives; Had experienced notable adverse events while on any oral contraceptive; Had a history of alcoholism or drug abuse; Had a relevant history or presence of respiratory, gastrointestinal, renal, hepatic,haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders; Had acute gastrointestinal symptoms at the time of screening or admission to the first period; Had a significant infection or inflammatory process at the time of screening or admission to the first period; Had a relevant surgical history; Had a relevant family history; Had a history of relevant drug hypersensitivity (e.g., carbamazepine or oxcarbazepine); Had used relevant prescription or overthecounter medication within 2 weeks ofadmission to the first period; Consumed more than 14 units of alcohol a week; Had participated in any clinical trial within 3 months prior to screening; Had previously received BIA 2093; Had donated or received any blood or blood products within 2 months prior to screening; Was unlikely to cooperate with the requirements of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>